L
Lily Q. Li
Researcher at Eli Lilly and Company
Publications - 9
Citations - 628
Lily Q. Li is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Migraine & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 486 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik,Lee S. Rosen,Sara M. Tolaney,Anthony W. Tolcher,Jonathan W. Goldman,Leena Gandhi,Kyriakos P. Papadopoulos,Muralidhar Beeram,Drew W. Rasco,John Hilton,Aejaz Nasir,Richard P. Beckmann,Andrew E. Schade,Angie D. Fulford,Tuan S. Nguyen,Ricardo Martinez,Palaniappan Kulanthaivel,Lily Q. Li,Martin Frenzel,Damien M. Cronier,Edward M. Chan,Keith T. Flaherty,Patrick Y. Wen,Geoffrey I. Shapiro +23 more
TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.
Proceedings ArticleDOI
Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer
Amita Patnaik,Lee S. Rosen,Sara M. Tolaney,Anthony W. Tolcher,Jonathan W. Goldman,Leena Gandhi,Kyriakos P. Papadopoulos,Muralidhar Beeram,Drew W. Rasco,Scott P. Myrand,Palaniappan Kulanthaivel,Lily Q. Li,Martin Frenzel,Damien M. Cronier,Edward M. Chan,Keith T. Flaherty,Patrick Y. Wen,Geoffrey I. Shapiro +17 more
TL;DR: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer is evaluated.
Journal ArticleDOI
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Jeffrey R. Infante,Amita Patnaik,Claire F. Verschraegen,Claire F. Verschraegen,Anthony J. Olszanski,Montaser Shaheen,Howard A. Burris,Anthony W. Tolcher,Kyriakos P. Papadopoulos,Muralidhar Beeram,Scott M. Hynes,Jennifer Leohr,Aimee Bence Lin,Lily Q. Li,Anna McGlothlin,Daphne L. Farrington,Eric H. Westin,Eric H. Westin,Roger B. Cohen,Roger B. Cohen +19 more
TL;DR: Prophylactic pegfilgrastim reduced neutropenia frequency and severity, allowing administration of higher litronesib doses, but increases in the incidences of mucositis and stomatitis were observed.
Journal ArticleDOI
Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Franck Morschhauser,Kamal Bouabdallah,Stephan Stilgenbauer,Catherine Thieblemont,Martin Wolf,Sophie de Guibert,Florian Zettl,Marjo Hahka-Kemppinen,David Xiaohui Wang,Patrick Brueck,Charles W. Caldwell,Richard P. Beckmann,Lawrence M. Gelbert,Damien M. Cronier,Ji Lin,Lily Q. Li,Edward M. Chan,Michael Pfreundschuh,Martin Wilhem,Georg Hess +19 more
TL;DR: Preliminary investigator assessment indicates that single agent therapy with abemaciclib was associated with stable disease for 9 patients and partial response for 5 patients, including durable disease control in patients with advanced non-hematologic malignancies.
Journal ArticleDOI
Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study.
Franck Morschhauser,Kamal Bouabdallah,Stephan Stilgenbauer,Catherine Thieblemont,Sophie de Guibert,Florian Zettl,Lawrence M. Gelbert,P. Kellie Turner,Siva Rama Prasad Kambhampati,Li Li,Lily Q. Li,Sean Buchanan,Susana Barriga,Melissa M. Bear,Martin Wilhelm,Georg Hess +15 more
TL;DR: Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma – a phase II study.